154 related articles for article (PubMed ID: 24165976)
21. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
Peeva E; Hodge MR; Kieras E; Vazquez ML; Goteti K; Tarabar SG; Alvey CW; Banfield C
Br J Clin Pharmacol; 2018 Aug; 84(8):1776-1788. PubMed ID: 29672897
[TBL] [Abstract][Full Text] [Related]
22. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.
Hao Y; Chapuy B; Monti S; Sun HH; Rodig SJ; Shipp MA
Clin Cancer Res; 2014 May; 20(10):2674-83. PubMed ID: 24610827
[TBL] [Abstract][Full Text] [Related]
23. Current and future role of fedratinib in the treatment of myelofibrosis.
Ragheb M; Harrison CN; McLornan DP
Future Oncol; 2020 Feb; 16(6):175-186. PubMed ID: 31971457
[TBL] [Abstract][Full Text] [Related]
24. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
[TBL] [Abstract][Full Text] [Related]
25. JAK2 Inhibition by Fedratinib Reduces Osteoblast Differentiation and Mineralisation of Human Mesenchymal Stem Cells.
AlMuraikhi N; Alaskar H; Binhamdan S; Alotaibi A; Kassem M; Alfayez M
Molecules; 2021 Jan; 26(3):. PubMed ID: 33503825
[TBL] [Abstract][Full Text] [Related]
26. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
[TBL] [Abstract][Full Text] [Related]
28. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
Shi JG; Chen X; Emm T; Scherle PA; McGee RF; Lo Y; Landman RR; McKeever EG; Punwani NG; Williams WV; Yeleswaram S
J Clin Pharmacol; 2012 Jun; 52(6):809-18. PubMed ID: 21602517
[TBL] [Abstract][Full Text] [Related]
29. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
[TBL] [Abstract][Full Text] [Related]
30. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
Okabe S; Tauchi T; Katagiri S; Tanaka Y; Ohyashiki K
J Hematol Oncol; 2014 Apr; 7():37. PubMed ID: 24775308
[TBL] [Abstract][Full Text] [Related]
31. Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant.
Hoch M; van Gorsel H; van Gerven J; Dingemanse J
J Clin Pharmacol; 2014 Sep; 54(9):979-86. PubMed ID: 24691844
[TBL] [Abstract][Full Text] [Related]
32. Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).
Zhou T; Georgeon S; Moser R; Moore DJ; Caflisch A; Hantschel O
Leukemia; 2014 Feb; 28(2):404-7. PubMed ID: 23823659
[No Abstract] [Full Text] [Related]
33. Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis.
Schiffer M; Kowalski A; Zhao J; Bewersdorf JP; Lewis RS; Zeidan AM
Drugs Today (Barc); 2020 Dec; 56(12):755-768. PubMed ID: 33332482
[TBL] [Abstract][Full Text] [Related]
34. JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells.
Oh Y; Lee JS; Lee JS; Park JH; Kim HS; Yoon S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562984
[TBL] [Abstract][Full Text] [Related]
35. Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.
Davis RR; Li B; Yun SY; Chan A; Nareddy P; Gunawan S; Ayaz M; Lawrence HR; Reuther GW; Lawrence NJ; Schönbrunn E
J Med Chem; 2021 Feb; 64(4):2228-2241. PubMed ID: 33570945
[TBL] [Abstract][Full Text] [Related]
36. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression.
Lee L; Niu H; Goelzer P; Rueger R; Deutsch J; Busse-Reid R; DeSchepper S; Blotner S; Barrett J; Weissgerber G; Peck R
J Clin Pharmacol; 2010 Dec; 50(12):1397-405. PubMed ID: 20386016
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Pardanani A; Gotlib JR; Jamieson C; Cortes JE; Talpaz M; Stone RM; Silverman MH; Gilliland DG; Shorr J; Tefferi A
J Clin Oncol; 2011 Mar; 29(7):789-96. PubMed ID: 21220608
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe
Tang Y; Liu W; Wang W; Fidler T; Woods B; Levine RL; Tall AR; Wang N
Cardiovasc Drugs Ther; 2020 Apr; 34(2):145-152. PubMed ID: 32086626
[TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration.
Muehlan C; Boehler M; Brooks S; Zuiker R; van Gerven J; Dingemanse J
J Psychopharmacol; 2020 Mar; 34(3):326-335. PubMed ID: 31642731
[TBL] [Abstract][Full Text] [Related]
40. Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke's encephalopathy.
Hazell AS; Afadlal S; Cheresh DA; Azar A
Neurosci Lett; 2017 Mar; 642():163-167. PubMed ID: 28109775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
